Thursday 25 April 2024
Internal Reference Number: FOI_6289
Date Request Received: 10/09/2021 00:00:00
Date Request Replied To: 11/11/2021 00:00:00
This response was sent via: By Email
Request Summary: Usage of Biologic drugs
Request Category: Companies
| Question Number 1: Could you please provide the numbers of patients treated in the last 3 months by the Gastroenterology department (for any medical condition) with the following biologic drugs: • Adalimumab - Humira • Adalimumab Biosimilar • Filgotinib • Golimumab • Infliximab - Remicade • Infliximab Biosimilar • Tofacitinib • Ustekinumab • Vedolizumab | |
| Answer To Question 1: Adalimumab - Humira 6 Adalimumab - Biosimilar 62 Filgotinib 0 Golimumab 2 Infliximab - Remicade 7 Infliximab - Biosimilar 114 Tofacitinib 1 Ustekinumab 34 Vedolizumab 36 | |
| Question Number 2: How many patients were treated in the last 3 months for Crohn’s Disease ONLY with the following biologic drugs: • Adalimumab - Humira • Adalimumab Biosimilar • Golimumab • Infliximab - Remicade • Infliximab Biosimilars • Ustekinumab • Vedolizumab | |
| Answer To Question 2: Adalimumab (Humeria) 9 Adalimumab (biosimilar) 62 Infliximab 5 Inflectra (infliximab biosimilar) 59 Golimumab 0 (not for Crohns patients) Ustekinumab 33 Vedolizumab 12 | |
| To return to the list of all the FOI requests please click here |
Our staff at Salisbury District Hospital have long been well regarded for the quality of care and treatment they provide for our patients and for their innovation, commitment and professionalism. This has been recognised in a wide range of achievements and it is reflected in our award of NHS Foundation Trust status. This is afforded to hospitals that provide the highest standards of care.
